KURA

Business Context and Reporting Period

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines for cancer. The filing covers the quarterly period ended September 30, 2025. The company's lead product candidate is ziftomenib, a menin inhibitor for acute myeloid leukemia (AML), which is currently under Priority Review by the FDA with a PDUFA target action date of November 30, 2025. The company also has programs for darlifarnib (KO-2806) and tipifarnib.

Key Financial Metrics

Note: Cash and short-term investments as of Dec 31, 2024 were $727.4 million ($224.5M cash + $502.9M investments). As of Sept 30, 2025, this total was $549.7 million ($95.3M cash + $454.4M investments).

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $20.8 million in collaboration revenue for Q3 2025, primarily from the Kyowa Kirin License Agreement, compared to zero revenue in Q3 2024. This includes revenue from development services and cost-share reimbursements.
• Expense Growth: Operating expenses increased significantly, driven by higher Research and Development (R&D) costs ($67.9M in Q3 2025 vs. $41.7M in Q3 2024). The increase is attributed to registration-directed clinical trials for ziftomenib and combination trials.
• Liquidity Position: Cash and cash equivalents decreased from $224.5 million at year-end 2024 to $95.3 million at Q3 2025. Total cash, cash equivalents, and short-term investments declined from $727.4 million to $549.7 million due to operating cash outflows of $181.3 million for the nine months ended September 30, 2025.
• Debt: The company has a term loan facility with approximately $9.7 million in total debt (current and long-term) as of September 30, 2025.

Guidance, Outlook, and Risks

• Regulatory Milestone: The FDA has accepted the New Drug Application (NDA) for ziftomenib for relapsed/refractory NPM1-mutated AML and assigned a PDUFA target action date of November 30, 2025.
• Clinical Progress: The company has initiated Phase 3 registrational trials (KOMET-017) for ziftomenib in newly diagnosed AML. A $30.0 million milestone payment was received in November 2025 (subsequent to the period end) upon dosing the first patient in the second KOMET-017 trial.
• Liquidity Outlook: Management believes current cash and investments ($549.7 million) combined with anticipated collaboration funding will fund operations into 2027 and support the ziftomenib AML program through topline results from KOMET-017.
• Risks: Key risks include the potential for FDA rejection of the ziftomenib NDA, failure of clinical trials, dependence on the Kyowa Kirin collaboration, and the need for substantial additional capital if profitability is not achieved.

Investor Verification Checklist

• FDA Decision Date: Verify the outcome of the FDA review for ziftomenib by the November 30, 2025 PDUFA date.
• Cash Burn Rate: Monitor quarterly cash usage to ensure the runway extends to 2027 as projected, given the $181.3 million operating cash burn in the first nine months of 2025.
• Kyowa Kirin Collaboration: Track the achievement of future development milestones and the potential exercise of the Field Expansion Option for ziftomenib.
• Debt Covenants: Review compliance with the term loan facility covenants, specifically the minimum cash covenant which requires holding cash equal to 55% of outstanding loan obligations if FDA approval is not received.
• Competition: Assess the market impact of Syndax Pharmaceuticals' approved menin inhibitor, Revuforj, which received approval for NPM1-mutated AML in October 2025.